Global acute bacterial skin and skin structure infections market is estimated to be valued at USD 3,842.5 Mn in 2024 and is expected to reach USD 5,701.7 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031.

Key Takeaways
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE and Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics LLC, Accord Healthcare Ltd., Merck and Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.

The key opportunities in the Acute Bacterial Skin And Skin Structure Infections Market Demand include a rise in incidence rates of skin infections due to increasing antibiotic resistance, growth in advanced treatment options and a strong product pipeline. With advancements in drug development, new classes of antibiotics are being explored to treat drug-resistant pathogens.

Technological developments such as new drug formulations including IV-to-oral step downs and anti-infective coating on medical devices are being researched to improve antibiotic treatment compliance and efficacy in ABSSSI.

Market Drivers
The key drivers of the acute bacterial skin and skin structure infections market include a growing elderly population who are more susceptible to various skin infections, increasing incidence of diabetes leading to poor wound healing and a rising prevalence of obesity. Furthermore, a lack of hygiene and overuse of antibiotics have contributed to antibiotic resistance, thereby requiring more potent drug treatments for ABSSI.

Current challenges in the Acute Bacterial Skin And Skin Structure Infections Market:

The ABSSSI market is facing challenges like increasing antibiotic resistance, need for better therapeutic options and lack of new drug approvals. Most infections are now resistant to many first line antibiotics which is reducing treatment effectiveness. There is an urgent need for novel drugs with new mechanisms of action. Developing new drugs is a long and risky process requiring huge investments. Limited funding and resources make it difficult for companies to develop innovative therapies for ABSSSI.

Get more insights on Acute Bacterial Skin And Skin Structure Infections Market